{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:17:36Z","timestamp":1785838656728,"version":"3.56.0"},"reference-count":35,"publisher":"The Journal of Rheumatology","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2018,4,20]]},"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>Obese patients with rheumatoid arthritis (RA) report more joint swelling and tenderness and often have poorer responses to therapy than nonobese patients. The aim of this posthoc analysis of the MUSICA trial was to compare imaging and clinical disease activity measures in obese and nonobese patients with RA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>MUSICA evaluated methotrexate (MTX) 20 mg\/week versus 7.5 mg\/week in combination with adalimumab (ADA) in RA patients with an inadequate response to MTX. Patients were categorized by baseline body mass index as normal (&lt; 25), overweight (\u2265 25 to &lt; 30), or obese (\u2265 30). Synovial vascularity and hypertrophy, swollen and tender joint counts (SJC and TJC), American College of Rheumatology (ACR) responses, and low disease activity (LDA), defined as Clinical Disease Activity Index &lt; 10 and 28-joint count Disease Activity Score using C-reactive protein (DAS28-CRP) &lt; 3.2, were assessed at weeks 12 and 24.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Patient characteristics were similar among groups at baseline. Obese patients had numerically smaller changes from baseline to weeks 12\/24 in SJC, TJC, DAS28-CRP, and synovial hypertrophy and vascularity versus nonobese patients. Significantly fewer obese patients reached ACR20\/50 at weeks 12 and 24, and LDA at Week 12; this difference was especially apparent in patients receiving 7.5 mg\/week MTX but was no longer significant at Week 24.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>Obese patients with RA had worse clinical and ultrasonographic responses than nonobese patients, which were partly overcome with time. Obese patients may experience better and faster clinical improvements if ADA is initiated with high-dose (20 mg\/week) rather than low-dose MTX. [<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"ClinicalTrials.gov\" xlink:type=\"simple\">ClinicalTrials.gov<\/jats:ext-link>:<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01185288\">NCT01185288<\/jats:ext-link>]<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.171232","type":"journal-article","created":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T11:25:15Z","timestamp":1535801115000},"page":"1628-1635","source":"Crossref","is-referenced-by-count":16,"title":["Clinical Responses and Synovial Vascularity in Obese Rheumatoid Arthritis Patients Treated with Adalimumab and Methotrexate"],"prefix":"10.3899","volume":"45","author":[{"given":"Gurjit S.","family":"Kaeley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daryl K.","family":"MacCarter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aileen L.","family":"Pangan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmina","family":"Kalabic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veena K.","family":"Ranganath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2018,9,1]]},"reference":[{"key":"2025021012250875000_45.12.1628.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62037-5"},{"key":"2025021012250875000_45.12.1628.2","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/art.30291","article-title":"Adipocytokines as driving forces in rheumatoid arthritis and related inflammatory diseases?","volume":"63","author":"Neumann","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2025021012250875000_45.12.1628.3","doi-asserted-by":"publisher","DOI":"10.1079\/PNS2005428"},{"key":"2025021012250875000_45.12.1628.4","doi-asserted-by":"crossref","first-page":"576","DOI":"10.3389\/fimmu.2014.00576","article-title":"Obesity as a risk and severity factor in rheumatic diseases (autoimmune chronic inflammatory diseases)","volume":"5","author":"Gremese","year":"2014","journal-title":"Front Immunol"},{"key":"2025021012250875000_45.12.1628.5","doi-asserted-by":"publisher","DOI":"10.1159\/000289203"},{"key":"2025021012250875000_45.12.1628.6","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1002\/acr.23229","article-title":"The impact of obesity and adiposity on inflammatory markers in patients with rheumatoid arthritis","volume":"69","author":"George","year":"2017","journal-title":"Arthritis Care Res"},{"key":"2025021012250875000_45.12.1628.7","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21710"},{"key":"2025021012250875000_45.12.1628.8","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21768"},{"key":"2025021012250875000_45.12.1628.9","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21978"},{"key":"2025021012250875000_45.12.1628.10","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/acr.22932","article-title":"Impact of obesity on remission and disease activity in rheumatoid arthritis: a systematic review and meta-analysis","volume":"69","author":"Liu","year":"2017","journal-title":"Arthritis Care Res"},{"key":"2025021012250875000_45.12.1628.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2006.12.003"},{"key":"2025021012250875000_45.12.1628.12","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-011-1885-z"},{"key":"2025021012250875000_45.12.1628.13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205544"},{"key":"2025021012250875000_45.12.1628.14","doi-asserted-by":"publisher","DOI":"10.1002\/art.23033"},{"key":"2025021012250875000_45.12.1628.15","first-page":"2350","article-title":"Relation between body mass index and radiological progression in patients with rheumatoid arthritis","volume":"30","author":"Kaufmann","year":"2003","journal-title":"J Rheumatol"},{"key":"2025021012250875000_45.12.1628.16","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12891-017-1406-7","article-title":"Joint-specific assessment of swelling and power Doppler in obese rheumatoid arthritis patients","volume":"18","author":"Bauer","year":"2017","journal-title":"BMC Musculoskelet Disord"},{"key":"2025021012250875000_45.12.1628.17","doi-asserted-by":"publisher","DOI":"10.1002\/art.22190"},{"key":"2025021012250875000_45.12.1628.18","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X12460116"},{"key":"2025021012250875000_45.12.1628.19","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151009"},{"key":"2025021012250875000_45.12.1628.20","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1002\/art.39751","article-title":"Changes in ultrasonographic vascularity upon initiation of adalimumab combination therapy in rheumatoid arthritis patients with an inadequate response to methotrexate","volume":"68","author":"Kaeley","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025021012250875000_45.12.1628.21","doi-asserted-by":"publisher","DOI":"10.1136\/ard.60.7.641"},{"key":"2025021012250875000_45.12.1628.22","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-14-0283"},{"key":"2025021012250875000_45.12.1628.23","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12154"},{"key":"2025021012250875000_45.12.1628.24","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.metabol.2017.04.005","article-title":"Macrophage functions in lean and obese adipose tissue","volume":"72","author":"Thomas","year":"2017","journal-title":"Metabolism"},{"key":"2025021012250875000_45.12.1628.25","doi-asserted-by":"publisher","DOI":"10.1002\/art.30136"},{"key":"2025021012250875000_45.12.1628.26","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/MEG.0000000000000544","article-title":"Comparative analysis of the influence of clinical factors including BMI on adalimumab and infliximab trough levels","volume":"28","author":"Bond","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2025021012250875000_45.12.1628.27","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12509"},{"key":"2025021012250875000_45.12.1628.28","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1998.t01-1-00790.x"},{"key":"2025021012250875000_45.12.1628.29","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.clinthera.2018.01.002","article-title":"Methotrexate dose in patients with early rheumatoid arthritis impacts methotrexate polyglutamate pharmacokinetics, adalimumab pharmacokinetics, and efficacy: pharmacokinetic and exposure-response analysis of the CONCERTO Trial","volume":"40","author":"Goss","year":"2018","journal-title":"Clin Ther"},{"key":"2025021012250875000_45.12.1628.30","unstructured":"Humira (adalimumab) . Highlights of Information. [Internet. Accessed July 9, 2018.] Available from: www.rxabbvie.com\/pdf\/humira.pdf"},{"key":"2025021012250875000_45.12.1628.31","first-page":"1709","article-title":"Patients with rheumatoid arthritis treated with methotrexate (MTX): concentrations of steady-state erythrocyte MTX correlate to plasma concentrations and clinical efficacy","volume":"35","author":"Hornung","year":"2008","journal-title":"J Rheumatol"},{"key":"2025021012250875000_45.12.1628.32","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.033399"},{"key":"2025021012250875000_45.12.1628.33","doi-asserted-by":"publisher","DOI":"10.1002\/art.20460"},{"key":"2025021012250875000_45.12.1628.34","doi-asserted-by":"crossref","first-page":"e000363","DOI":"10.1136\/rmdopen-2016-000363","article-title":"Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a 76-week prospective study","volume":"3","author":"Takahashi","year":"2017","journal-title":"RMD Open"},{"key":"2025021012250875000_45.12.1628.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2012.03.016"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.171232","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T20:26:27Z","timestamp":1739219187000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.171232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,1]]},"references-count":35,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2018,12,1]]},"published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.3899\/jrheum.171232"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.171232","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,1]]}}}